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It has been universally acknowledged that the increase in cardiac and vascular stiffness is due to the
formation of advanced glycosylation end-products (AGEs). Research on the stable form of 3-(carbox-
ymethyl)-4-methylthiazol bromide sodium salt (C6H7BrNNaO2S) showed that it had a notable effect on
breaking the AGEs. Two compounds with novel structures, zwitterionic 3-(carboxymethyl)-4-
methylthiazol (C6H7O2NS) and a dipolymer (C12H15O4N2S2Br) complex, were obtained. When
compared with the forms of sodium salt and dipolymer, zwitterion had an obvious advantage in stability,
solubility, synthesis and pH, which made the zwitterion a promising drug. The structure of sodium salt,
dipolymer and zwitterion was comparatively analyzed by such methods as single crystal X-ray diffrac-
tion, ESI-MS, 1H NMR, FT-IR and in situ IR.
 2013 The Authors. Published by Elsevier Masson SAS. Open access under CC BY license.1. Introduction
Excessive formation of advanced glycosylation end-products
(AGEs) is a signiﬁcant factor contributing to the development of
cardiovascular diseases associated with aging, diabetes and hy-
pertension as has been widely documented [1,2]. Glucose can react
non-enzymatically with long-lived proteins, such as collagen and
lens crystallin, linking them together to form cross-links, that will
eventually generate advanced glycosylation end-products (AGEs).
Formation of AGEs leads to increasing levels of oxidative stress, and
their accumulation in serum, kidney and vascular tissues is a key
risk marker for microvascular complications, especially in diabetic
patients [3,4].
To decrease the number of these cross-links, some compounds
have been discovered, the majority of which belong to a class of
thiazolium derivatives such as phenacylthiazolium bromide (PTB)r Masson SAS. Open access under CCand ALT-711 [5e7]. These compounds can selectively cleave di-
ketone bridges of two adjacent carbonyl groups that might form
intermolecular cross-links with amino acid side chains and thus
appears to reverse cross-linking both in vitro and in vivo [8e10].
Based on the principle of “cross-link breakers”, we designed a
series of N-(carboxymethyl) thiazolium derivatives [11,12]. By
screening from these hundreds of betaines, some active candidates,
having a common structure of ester, were identiﬁed. Subsequently,
pharmacokinetic studies on these active candidates in our labora-
tory indicated that the functional ester group was predominantly
metabolized into carboxyl in vivo. Therefore, we believe that these
compounds play the role of “cross-link breaker”.
According to the exact molecular mechanism, we reduced these
N-(carboxymethyl) thiazolium derivatives, and designed the
simplest representative of these derivatives, namely a 3-(carbox-
ymethyl)-4-methylthiazol bromide sodium salt (C6H7BrNNaO2S).
The satisfactory efﬁcacy of which in vivo had been conﬁrmed by
experiments performed in rats. However, to our great surprise, the
results of X-ray analysis revealed that this compound including
both sodium acetate and quaternary ammonium salt was not stable
enough for isolation, possibly because the sodium and bromine
cannot regularly exist in one molecule, a portion of which cohered
in the form of NaBr. Subsequently, dipolymer (C12H15O4N2S2Br) and
zwitterion (C6H7O2NS) were obtained by synthesis. After a series of BY license.
Scheme 1. Synthesis of compounds 2e4.
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terion form has the most promising druggability of these potential
“cross-link breakers”.
To date although several zwitterions have been identiﬁed, an
overwhelming majority of them stably exist in the form of coor-
dination complexes [13,14]. Therefore, only a few of their structures
have been determined in the solid state [15], so that there has been
very little drug design based on zwitterionic structure appearing on
the market. In this paper, a novel thiazole derivative, namely the
zwitterionic 3-(carboxymethyl)-4-methylthiazol, which has a
structure analogous to amino acid and a zwitterionic form con-
taining a positively charged quaternary ammonium and a nega-
tively charged carboxylate, is reported. Synthesis, structural
characterizations and druggability studies of the three compounds
will be described below.
2. Results and discussion
2.1. Synthetic studies
To determine the most stable structure of this “cross-link
breaker”, several syntheses are carried out and three forms of theTable 1
Crystallographic data and details of structure reﬁnement of compounds 2e4.
Complex 2 3
Empirical formula C12H14Br2N2Na2O4S2 C1
Formula weight 520.20 39
Crystal system Triclinic M
Space group P2(1)/n P2
a (Å) 8.9000(18) 5.1
b (Å) 9.4095(19) 12
c (Å) 12.028(2) 13
a () 92.82 90
b () 109.00 97
g () 104.11 90
V [Å3] 914.5(3) 81
Z 2 2
rcalcd [Mg/m3] 1.904 1.6
F(000) 520 40
Crystal size (mm) 0.40  0.30  0.10 0.2
q range for data collection 2.25e25.03 2.3
Limiting indices 10  h  10, 11  k  11, 14  l  14 6
Reﬂections collected/unique 5591/3046 [R(int) ¼ 0.0303 54
Temperature (K) 293(2) 11
Data/restraints/parameters 3046/4/217 14
Final R indices [I > 2d(I)] R1 ¼ 0.0509 R1
R indices (all data) wR2 ¼ 0.1391 wR
Largest diff. peak and hole (Å3) 0.960 and 0.676 0.4target compounds (2e4) are obtained (Scheme 1). In the reaction to
2 and 3, the quantity of base must be strictly restricted to the
equimolar amount of the carboxylic derivation or else the redun-
dant base would not be easily separated from the target sodium
salt. In contrast to reactions 1 and 2, reaction 3 has the obvious
predominance in outcome and reﬁnement.
2.2. Structural studies
2.2.1. X-ray crystallography
The crystal data and details of structure reﬁnement of com-
pounds 2e4 are given in Table 1.
The asymmetric unit is shown in Fig. 1. In the single crystal
structure of 2, two donor sites of one ligand link to the sodium
cation, Na2, via the coordination bond Na2eO3 and Na2eO4 (Na2e
O3 ¼ 2.530(6) Å and Na2eO4 ¼ 2.410(6) Å), while the two donor
sites coming from different ligands connect to Na1 via coordination
bond Na1eO3 and Na1eO1 (Na1eO3 ¼ 2.336(7) Å and Na1e
O1¼ 2.351(7) Å). Although the two bromine atoms in this molecule
are apparently isolated, the distance from bromine to sodium (Br1e
Na1 ¼ 2.869(3) and Br2eNa2 ¼ 2.864(3) Å) suggests that there is a
great probability of bonding between them.4
2H15BrN2O4S2 C6H7NO2SH2O
5.29 175.2
onoclinic Orthorhombic
(1)/n P2(1)/n
907(10) 5.6082(11)
.092(2) 8.4615(17)
.052(3) 16.064(3)
90
.96 90
90
1.3(3) 762.3(3)
4
18 1.527
0 368
0  0.10  0.10 0.20  0.18  0.10
1e25.01 2.54e27.89
h  6, 14  k  14, 15  l  14 7h  6, 11  k  11, 21  l  21
18/1424 [R(int) ¼ 0.0303] 8477/1822 [R(int) ¼ 0.0403]
3(2) 143(2)
24/1/102 1822/0/110
¼ 0.0336 R1 ¼ 0.0266
2 ¼ 0.0851 wR2 ¼ 0.0645
63 and 0.989 0.232 and 0.211
Fig. 1. The X-ray crystal structure of 2, with displacement ellipsoids drawn at the 50%
probability level.
Fig. 2. The X-ray crystal structure of 3, with displacement ellipsoids drawn at the 50%
probability level.
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structure in which a proton (linked to an alternative zwitterion
through the formation of a hydrogen bond) is shared by two
zwitterion molecules; this structure is also in accordance with the
elemental analysis [16,17]. The active proton is maintained moving
between two zwitterions; when one bond distance of O2eH is
0.84(4), the other (O2A.H) is 1.62(4) Å (Table 2), with an OeH.O
angle of 172(6), keeping conversion at all times (Table 2). The Oe
CeO angles of the carboxyl groups are 126.5, with the bond length
of the two OeC being 1.226(3) Å and 1.281(3) Å, respectively, while
the skewness parameter of 0.055(3) Å shows that the crystal
environment of the proton favors the O2 site (Fig. 2). In the mass
spectrum data, the signal atm/z¼ 158 for the single acid unit is the
most intense peak, but a dimeric cation at m/z ¼ 315 is also
observed.
The negative charge of COO-, Br- and two positive charged ni-
trogen atoms keep the charge balance in this hydrogen-bonded
dimer. The result of this special structure may come from the
weak acidic property of 3 that leads to a proton barely dissociating
from the carboxylic acid.
In our attempt to react 4-methylthiazole with sodium bro-
moacetate, a compound inlaid in several water molecules (Fig. 3) is
obtained. Due to the presence of unordered fragmentation in the
water molecule, it is unlikely that the structure of this molecule can
be unambiguously determined.Table 2
Hydrogen bond lengths (Å) and bond angles () in 2e4.
DeH.A d(DeH) d(H.A) d(D.A) :(DHA)
2
O(2)eH(2A).S(2)a 0.851(5) 2.375(2) 3.227(6) 179.5(4)
O(4)eH(4A).S(1)b 0.858(5) 2.388(3) 3.246(6) 179.4(4)
3
O(2)eH(2).O(2)c 0.84(4) 1.62(4) 2.451(4) 172(6)
4
O(3)eH(3A).O(1) 0.84(3) 1.96(3) 2.8014(18) 172(2)
O(3)eH(3B).O(2)d 0.82(3) 2.07(3) 2.885(2) 178(2)
O(3)eH(3B).O(1)d 0.82(3) 2.67(2) 3.2260(17) 127(2)
a Symmetry code: x, y, z.
b Symmetry code: x, y þ 1, z þ 1.
c Symmetry code: x þ 2, y þ 2, z þ 1.
d Symmetry code: x  1/2, y þ 1/2, z þ 1.Structure of 4, an absolute zwitterion, without any extraneous
component, is in good agreement with those measured by
elemental analysis. This zwitterion is stabilized by charge delocal-
ization (Fig. 4).
After a single crystal (Fig. 5) was obtained, it was puzzlingly
determined to contain a water molecule and this has been veriﬁed
by multiple experiments [18]. The thiazole ring is almost planar
with a maximum displacement of 0.009 Å for the C3 atoms. The
carboxymethyl group involving atoms C5, C6, O1 and O2 is located
above the thiazole plane. Also, the CeCOO group, which is also
planar, intersects with the thiazole plane at an angle of 79.62 [16].
The bond lengths of C6eO1 (1.2525 Å) and C6eO2 (1.2530 Å) are
very similar, with an O1eC6eO2 angle of 127.56, which suggests
the two atoms have identical chemical properties. The oxygen
atoms, O1 and O2, are directed toward the hydrogen atoms of
different water molecules with distances ranging from 1.96 to
2.07 Å, and hydrogen atoms linking C1 and C4 also interact weakly
with the oxygen atoms of water by means of hydrogen bonding
(Fig. 6). From what has been discussed above, we can reason that
water molecules are absolutely indispensable to the formation of a
stabilizing single crystal [19]. Some short CeH.O contacts pre-
senting among layers of the two units as well as van der Waals
forces between the oxygen and sulfur atoms of the next thiazole
ring all contribute to the stabilization of the crystal structure [20].
In the mass spectrum, the signal at m/z ¼ 158 [M þ H]þ for the
single unit is the most intense peak, a dipolymer at m/z ¼ 315
[2M þ H]þ, and a trimerization at m/z ¼ 472 [3M þ H]þ is also
observed.
2.2.2. 1H NMR spectroscopy
In particular, as structural change (from 1 to 3, to 2, to 4), the
chemical shifts of protons (HC1, HC3 and HC5) display a law of
diminishing (Table 3). In DMSO, the 1H chemical shift of these
protons (Fig. 7) undergoes onlyminor changes on conversion of 1 to
3, 2 and 4 except in the case of the proton linking to C5. The signal ofFig. 3. A molecule inlaid in an unordered fragmentation of water.
Fig. 4. The zwitterion is stabilized by charge delocalization.
Fig. 6. The molecular packing and hydrogen-bonding scheme of 4.
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can also be observed when we contrast 3 with 4 [21].
Through analysis, we raised that the change of charge distri-
bution contributed to this phenomenon. In compound 1, the exis-
tence of an HeO bond transfers the electron density of the
carboxylic group to H, so that the charge distribution between the
Nþ atom and the COO leans toward the latter, which eventually
results in the electron density of C5 of 1 being weaker than 4.
Owing to every zwitterion sharing each Hþ moiety on average in
compound 3, the effect of HeO on shielding of C5 fades, which can
well explain why the chemical shift of 3e4 is approximately half
that of 1e4.
2.2.3. IR spectroscopy
The change of structure can also be observed in FT-IR spectra
(Fig. 8). Comparing 1 to 2, and 3, a number of weak/medium ab-
sorptions disappeared in the 2300e2800 cm1 range assigned to
CeH.Br vibrations. This observation reveals that the interactions
between bromine and cation in complex 2, 3 have changed
remarkably. In the spectrum of 2 and 4, the absorption assigned to
the n(C]O) vibrations of carboxy in the spectrum of complex 1 at
1731 cm1 vanish completely. However, the presence of strong
bands at 1374 and 1368 cm1 corresponding to a ns(COO)
stretching vibration is indicative of the existence of COO, which
can also be conﬁrmed by the broad and intense band at about
1625 cm1 caused mainly by the overlaying of the band assigned to
n(C]O) and n(C]C) vibrations [16]. Given that the two units
(RCOOH and RCOO) are linked via homoconjugated intermolecular
hydrogen (OeH.O) in one complex, the intense bands at 1725 and
1374 cm1 are all found in the spectrum of 3 [17].
We can also observe that the spectrum of 2 is nearly the same as
4, which indicates that the organic part (zwitterion) of compound 2
is almost in the same chemical environment as 4 and also suggests
that the Br as well as the Naþ exists in a free state in compound 2.
This presumption can reasonably explain why the structure of
compound 2 is barely in accordance with the elemental analysis.Fig. 5. The X-ray crystal structure of 4, with displacement ellipsoids drawn at the 50%
probability level.2.2.4. In situ IR
To study the change of COO and COOH in the reaction of pre-
paring 4,we attempted to use in situ IR to monitor the reaction
system. The consumption of 1 and producing of 4 can be observed
indirectly in ﬁgure above (Fig. 9), especially after the solvent
spectrum is subtracted. At last, to our surprised, we found this re-
action ﬁnished in several seconds.
It can be seen from the graph (Fig. 10) that the intensity of the
absorption peak at 1731 cm1, the characteristic peak attributed to
COOH, increase markedly after b point, and fade away after c point.
This trend shows that the COOH vanish quickly after reacting with
propylene oxide.
Contrary to the quickly vanishing of absorption peak at
1731 cm1, after c point, the intensity of the absorption peak at
1374 cm1, characteristic peak of COO, soared and then remained
stable. This result indicates that the reaction is completed quickly
and nearly all the COOH converted into COO in a very short time.
It was very interesting that from the graph (Fig. 10), we noted an
obvious strengthen of the absorption peak at 1374 cm1 (from b to
c). This phenomenon implies the COO appeared after adding
compound 1 due to the rapid dissociation of COOH of compound 1
into COO and Hþ.2.3. Druggability studies
In vivo efﬁcacy has been conﬁrmed by experiments performed
in rats, showing that the increased arterial stiffness associated with
diabetes can be reversed by a short treatment with the cross-link
breaker 3-(carboxymethyl)-4-methylthiazol bromide sodium salt
(2). However, owing to the free state of the Br and Naþ, the
druggability of compound 2 is terrible.Table 3
1H chemical shifts (ppm) in DMSO of the protons in a series of betaines.
Compound Ring protons HC4 HC5
HC1 HC3
C6H5SNþCH2COOH$Br (1) 8.05 10.17 2.47 5.51
C6H5SNþCH2COOHCOOCH2NþSC6H5$Br (3) 7.99 10.09 2.43 5.16
C6H5SNþCH2COONa$Br (2) 7.90 9.98 2.41 4.79
C6H5SNþCH2COO (4) 7.90 9.97 2.41 4.76
Fig. 7. Enumeration of the carbon atoms in the original nucleus.
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3 is lower than that of 2, resulting from the breaking of the
hydrogen bond when compound 3 is dissolved in protonic solvent.
Because of this low pH, compound 3may act as a severe alimentary
tract irritant, which suggests that compound 3 is less likely to be
applied as a drug.
Compound 4, the product of structure optimizing based on
compound 2, displays outstanding properties in many ﬁelds, such
as stability, solubility, synthesis and pH. Given the structural sim-
ilarity between compound 4 and 2, we anticipate that they will be
similarly effective in breaking AGE cross-links, and relevant studies
on the biological activity of compound 4 have been ongoing in our
group. For all of the reasons, we conclude that compound 4 is a
good candidate for success in druggability.3. Conclusions
In the process of synthesizing the “cross-link breaker” 3-(car-
boxymethyl)-4-methylthiazol bromide sodium salt (2), three types
of structures were obtained: sodium salt (2), dipolymer (3) and
zwitterion (4). Through deliberate analysis with the method of
single crystal X-ray diffraction, EA, FT-IR, 1H NMR, ESI-MS and in
situ IR, we came to the conclusion that the zwitterionic 3-(car-
boxymethyl)-4-methylthiazol (4) has obvious advantages in its
physicochemical property and manufacturing feasibility that sug-
gest it would be a promising drug in its zwitterion form.Fig. 8. Solid state FT-IR spectra in4. Experimental
4.1. Materials
4-methylthiazole (SCRC), bromoacetic acid (Beijing chemicals),
propylene (SCRC), sodium methanolate (Alfa) were used as
received. Methanol (Beijing chemicals) and ethanol (Beijing
chemicals) were dried and puriﬁed by standard methods.
4.2. Physical measurements
Microanalysis (C, H and N) was performed by the Analytical
Center at Peking University, on an Elementar Vario Micro Cube CHN
analyzer. Melting points were determined using an RY-1 apparatus
and the thermometer is uncorrected. The infrared spectra were
recorded on a NicoLET 6700 FT-IR Thermo Scientiﬁc spectropho-
tometer (KBr pellets, 4000e400 cm1). 1H NMR spectra were
recorded on a Varian Unity 400 MHz spectrometer. MS spectra
were obtained using an Applied Biosystems API-150EX LC/MSmass
spectrograph. 3D-FT-IR spectra were obtained from ReactIR iC10
with MCT Detector and a DiComp (Diamond) probe.
4.3. Synthesis
4.3.1. Synthesis of C6H7BrNNaO2S (2)
A solution of 4-methylthiazole (10 g, 0.10 mol) and 2-bromo-
acetic acid (15.2 g, 0.11 mol) was added to acetonitrile (70 ml), and
then the reaction was heated under reﬂux for 8 h. The solution was
ﬁltered after cooling and the precipitate was washed with acetone.
The dry white powder 1,obtained above (17.8 g, yield 74%), and
NaHCO3 (6.28 g, 0.07 mol) dissolved in dry methanol (90 ml) and
the whole solution was stirred for 5 h under ambient temperature
before it was diluted with ethanol (130 cm3). Colorless needlelike
crystal of 2 (14.6 g, yield 75%) was obtained after 12 h. Mol. Wt.
260.1; M.p. 182 C; MS: 158.2 [M  Na  Br þ H]þ; 1H NMR
(400 MHz, DMSO-d6 d ppm), 9.98 (1H, d, J ¼ 2.4 Hz), 7.90 (1H, d,
J ¼ 1.2 Hz), 4.79 (2H, s), 2.41 (3H, d, J ¼ 1.2 Hz).the different regions of 1e4.
Fig. 9. (A), (B) 3D-FT-IR spectrum fragments for the reaction of compound 1with propylene epoxide. The reaction was monitored from 0 to 70 min. a. Addition of water (4:00 min).
b. Addition of compound 1 (13:00 min). c. Addition of propylene epoxide (27:00 min).
S. Cao et al. / European Journal of Medicinal Chemistry 68 (2013) 89e95944.3.2. Synthesis of C12H15O4N2S2Br (3)
Compound 1 (10 g, 0.04 mol) with 1 equiv of CH3ONa (2.3 g,
0.04 mol) in methanol (70 ml) was carried out at ambient tem-
perature over 5 h. Acetone (100 ml) was added into the solvent and
the precipitate was separated by ﬁltration and then crystallized
from methanoleethanol. Colorless needlelike crystals of 3 (10.9 g,
yield 81%) were obtained after 12 h. Mol. Wt. 439.4; M.p. 205 C; 1H
NMR (400MHz, DMSO-d6 d ppm),10.09 (1H, d, J¼ 2.0 Hz), 7.99 (1H,
d, J ¼ 1.2 Hz), 5.16 (2H, s), 2.43 (3H, s); MS: 158 [M  Br]þ, 315
[2M  H]þ; Anal. calcd for C12H15O4N2S2Br: C 36.46, H 3.82, N 7.09,
Br 20.21. Found: C 36.27, H 4.01, N 7.15, Br 20.12%.
4.3.3. Synthesis of C6H7O2NS (4)
Compound 1 (10 g, 0.04 mol) was transformed into zwitterion
form (4) by dissolving in water (50 ml) and adding three times the
amount of propylene oxide (7.31 g, 0.12 mol). The solution wasFig. 10. Kinetic proﬁle (peak height vs time) of the intensity of the absorption peak at
1374 cm1 and 1731 cm1 for the reaction of preparing compound 4. a. Addition of
water (4:00 min). b. Addition of compound 1 (13:00 min). c. Addition of propylene
epoxide (27:00 min).stirred at room temperature for 12 h, and the ﬁnal pH was 7. Before
the aqueous layer was evaporated to dryness, it was extracted with
dichloromethane to remove bromohydrin, and then the remaining
solid was recrystallized from ethereethanol (1:3), giving the
slightly yellowish crystalline powder of 4 (5.2 g, yield 78%). Mol.
Wt. 157.2; M.p. 169 C; 1H NMR (400 MHz, DMSO-d6 d ppm), 9.97
(1H, d, J ¼ 2.8 Hz), 7.90 (1H, d, J ¼ 1.6 Hz), 4.76 (2H, s), 2.41 (3H, d,
J ¼ 0.8 Hz); 13C NMR (Methanol-d4), d 12.98, 56.71, 121.47, 148.36,
169.71; MS: 158 [M þ H]þ, 315 [2M þ H]þ, 472 [3M þ H]þ; Anal.
calcd for C12H15O4N2S2Br:C 45.85, H 4.49, N 8.91%. Found: C 45.65,
H 4.75, N 8.83%.4.4. X-ray crystallography
Colorless prism-shaped crystals of 2 suitable for X-ray diffrac-
tion were obtained from a MeOHeEtOAC mixture at 20 C, which
was also suitable for the preparation of single Crystals of 3 and 4.
X-ray diffraction data were collected on a Rigaku Saturn CCD
area detector. Computations were done using graphite mono-
chromatized Mo Ka radiation (l ¼ 0.71073 Å). Data reduction was
performed with Crystalclear (Rigaku/MSC Inc., 2005). Structure
solution and reﬁnement were performed on PCs by means of
SHELX-97 software package, and graphical representations of the
structures were made with SHELXTL (Bruker, 2002). All three
structures were solved by direct methods and reﬁned with full-
matrix least squares on F2 using the SHELX-97 program package.
All non-hydrogen atoms were reﬁned anisotropically, while
hydrogen atoms were located in subsequent different Fourier maps
and their positional and isotropic displacement parameters were
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